January Research Highlights

A roundup of the latest medical discoveries and faculty news at Cedars-Sinai.

Mount Sinai study finds SARS-CoV-2 induces robust antibody responses stable for at least 3 months

Research from the Mount Sinai Health System, just posted to pre-print server MedRxiv (https://www.medrxiv.org/content/10.1101/2020.07.14.20151126v1), shows that the vast majority (more than 90%) of infected individuals with mild-to-moderate COVID 19 experience robust IgG antibody responses against the viral spike protein. The researchers also show…

Sanford Burnham Prebys announces research agreement with Lilly for COVID-19 antibody research

Sanford Burnham Prebys Medical Discovery Institute today announced a research agreement with Eli Lilly and Company (Lilly) to characterize Lilly’s next-generation anti-SARS-CoV-2 antibodies. These collaborative studies aim to build on Lilly’s current portfolio of neutralizing antibodies by exploring novel cocktails, half-life extension technologies and strategies to further enhance potency.